Quantbot Technologies LP Buys Shares of 6,302 Apogee Therapeutics Inc. $APGE

Posted by Geri Gentry on Aug 27th, 2026

Quantbot Technologies LP bought a new stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) in the second quarter, Holdings Channel reports. The fund bought 6,302 shares of the company’s stock, valued at approximately $836,000.

Other large investors also recently modified their holdings of the company. TD Asset Management Inc lifted its stake in Apogee Therapeutics by 55.3% in the fourth quarter. TD Asset Management Inc now owns 129,290 shares of the company’s stock valued at $9,759,000 after purchasing an additional 46,050 shares during the last quarter. Vanguard Group Inc. increased its position in Apogee Therapeutics by 27.3% in the fourth quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company’s stock worth $215,709,000 after buying an additional 612,193 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Apogee Therapeutics by 7.3% in the first quarter. Bank of New York Mellon Corp now owns 126,757 shares of the company’s stock valued at $10,669,000 after buying an additional 8,673 shares during the period. Alberta Investment Management Corp bought a new stake in shares of Apogee Therapeutics in the second quarter valued at $9,955,000. Finally, Bank of America Corp DE lifted its position in shares of Apogee Therapeutics by 13.5% during the 1st quarter. Bank of America Corp DE now owns 900,871 shares of the company’s stock valued at $75,826,000 after buying an additional 107,176 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $133.63, for a total value of $2,672,600.00. Following the sale, the chief executive officer owned 995,987 shares in the company, valued at approximately $133,093,742.81. This trade represents a 1.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $134.17, for a total value of $737,935.00. Following the sale, the insider directly owned 168,498 shares of the company’s stock, valued at $22,607,376.66. This represents a 3.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 162,900 shares of company stock worth $20,344,950 in the last quarter. 24.30% of the stock is currently owned by company insiders.

Apogee Therapeutics Trading Up 0.1%

Shares of NASDAQ:APGE opened at $134.95 on Thursday. The company has a 50 day moving average of $132.21 and a 200 day moving average of $97.78. The stock has a market cap of $8.39 billion, a P/E ratio of -31.09 and a beta of 0.34. Apogee Therapeutics Inc. has a 12 month low of $35.39 and a 12 month high of $134.99.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.07). On average, equities analysts forecast that Apogee Therapeutics Inc. will post -4.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Rothschild & Co Redburn started coverage on Apogee Therapeutics in a research note on Friday, May 1st. They set a “buy” rating and a $140.00 price target for the company. Royal Bank Of Canada upped their price objective on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the company a “sector perform” rating in a report on Monday, June 8th. UBS Group downgraded shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and upped their price objective for the company from $100.00 to $135.11 in a report on Tuesday, June 23rd. Craig Hallum set a $135.11 target price on shares of Apogee Therapeutics and gave the stock a “hold” rating in a research note on Monday, June 22nd. Finally, Wedbush downgraded shares of Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 target price for the company. in a research note on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $124.43.

Check Out Our Latest Stock Analysis on Apogee Therapeutics

Apogee Therapeutics Profile

(Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.